BJERKHOLT ERIC 4

What Happened

• Eric Bjerkholt, Chief Financial Officer of Mirum Pharmaceuticals (MIRM), had restricted stock units convert to common shares on Jan 23, 2026 (2,667 shares) and sold 1,053 shares in an open-market transaction on Jan 26, 2026 for $96.19 each, generating $101,290 in proceeds.
• The filing shows 2,667 shares from the conversion were also disposed on Jan 23, 2026 at $0.00 — consistent with shares withheld/surrendered to cover tax withholding obligations tied to the RSU vesting.

Key Details

• Transaction dates and prices:
  • Jan 23, 2026: Conversion/exercise of derivative (2,667 shares). Same date shows 2,667 shares disposed at $0.00 (tax withholding).
  • Jan 26, 2026: Open-market sale of 1,053 shares at $96.19 each; proceeds $101,290.
• Shares owned after transaction: Not specified in the provided filing details.
• Footnotes of note:
  • F1: Each RSU equals a contingent right to one share (or cash equivalent).
  • F2: Shares were sold/withheld to cover tax withholding on RSU vesting.
  • F3: RSU vesting schedule: 1/3 each year beginning Jan 23, 2024 (full vesting in 3 years).
• Filing date/accession: Filed Jan 27, 2026 (appears timely based on transaction dates).

Context

• This filing reflects RSU conversion and routine tax withholding plus an open-market sale. The RSU conversion and withholding are administrative results of vesting; the separate market sale generated the reported cash proceeds.
• Such sales are often routine (tax-related or liquidity) and do not, by themselves, indicate the insider’s broader view of the company.